Share

5 Popular COVID-19 Articles Among Clinicians

Apr 20, 2020 | Hospital Solutions


We know that now more than ever it’s important to stay up-to-date on the news. Our team assembled some of the most read COVID-19 articles among clinicians over the last week.

 

The New York Times

Who Is Immune to the Coronavirus?

Given the incredibly contagious nature of COVID-19, Marc Lipsitch, an epidemiologist and infectious disease specialist, delves into who might be immune from the disease. Are there those who are naturally immune? Might there be 1,000x more cases out there than we even know of? Do people get lifelong immunity to coronavirus once they’ve had it once?

 

Becker's Hospital Review

State Rankings of COVID-19 Tests Performed

In the U.S., 2.83 million tests have been performed for the novel coronavirus, according to data from the COVID Tracking Project. Here, you’ll find a ranking of the number of tests performed in each state.

 

The New York Times

Some Doctors Moving Away from Ventilators for Virus Patients

As health officials around the world push to get more ventilators to treat coronavirus patients, some doctors are moving away from using the breathing machines when they can. Generally speaking, 40% to 50% of patients with severe respiratory distress die while on ventilators, experts say. So, how are physicians moving forward and why are they seeing this trend?

 

Scientific American

What Immunity to COVID-19 Really Means

In an ideal world, COVID-19 immunity would resemble that acquired by children who get chickenpox. Early research suggests we are in for a much more complex scenario, but one that time and unprecedented global cooperation might be able to untangle. Eventually, antibody tests could be the key to getting our lives and economies back on track. For now, they promise to give experts, officials, and citizens a clearer picture of the pandemic.

 

Nature

The COVID-19 Vaccine Development Landscape

The global vaccine R&D effort in response to the COVID-19 pandemic is unprecedented in terms of scale and speed. Given the imperative for speed, there is an indication that a vaccine could be available under emergency use or similar protocols by early 2021.